The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.
대표청구항▼
1. A solid form comprising a crystalline compound of formula 1: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the crystalline compound of formula 1 is a Form A crystal form of formula 1 having an X-ray powder diffraction pattern comprising peaks at approximate peak pos
1. A solid form comprising a crystalline compound of formula 1: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the crystalline compound of formula 1 is a Form A crystal form of formula 1 having an X-ray powder diffraction pattern comprising peaks at approximate peak positions of 17.26±0.10, 21.60±0.10, and 27.73±0.10 degrees 2θ and at least one peak at an approximate peak position of 9.68±0.10, 24.68±0.10, 25.48±0.10, and 29.08±0.10 degrees 2θ. 2. The solid form of claim 1, wherein the solid form is substantially free of a compound of formula IMP-1, formula IMP-2, formula IMP-3, or formula IMP-4: 3. The solid form of claim 2, wherein the solid form is substantially free of an amorphous compound of formula 1. 4. The solid form of claim 2, wherein the solid form is substantially free of the compound of formula IMP-1. 5. The solid form of claim 4, wherein the solid form has less than about 0.05% a/a of the compound of formula IMP-1. 6. The solid form of claim 2, wherein the solid form is substantially free of the compound of formula IMP-2. 7. The solid form of claim 6, wherein the solid form has less than about 0.05% a/a of the compound of formula IMP-2. 8. The solid form of claim 2, wherein the solid form is substantially free of the compound of formula IMP-3. 9. The solid form of claim 8, wherein the solid form has less than about 0.05% a/a of the compound of formula IMP-3. 10. The solid form of claim 2, wherein the solid form is substantially free of the compound of formula IMP-4. 11. The solid form of claim 10, wherein the solid form has less than about 0.05% a/a of the compound of formula IMP-4. 12. The solid form of claim 1, wherein the solid form is substantially free of other crystal forms of formula 1. 13. The solid form of claim 1 having an X-ray powder diffraction pattern further comprising peaks at approximate peak positions of 24.68±0.10 and 25.48±0.10 degrees 2θ. 14. The solid form of claim 13 having an X-ray powder diffraction pattern further comprising peaks at approximate peak positions of 9.68±0.10 and 29.08±0.10 degrees 2θ. 15. The solid form of claim 14 having an X-ray powder diffraction pattern further comprising peaks at approximate peak positions of 4.83±0.10, 16.12±0.10, 16.92±0.10, 17.75±0.10, 18.58±0.10, 18.89±0.10, 19.34±0.10, 19.69±0.10, 21.01±0.10, 22.46±0.10, 23.67±0.10, 24.33±0.10, 25.16±0.10, 25.96±0.10, 26.48±0.10, 29.43±0.10, and 29.84±0.10. 16. The solid form of claim 1, which has unit cell parameters consistent with the following approximate unit cell parameters: a=5.45 Å; b=5.16 Å; c=36.12 Å; α=90°; β=90°; γ=90°; V=1016.5 Å3, and Z=4. 17. The solid form of claim 1, wherein the solid form is substantially free of one or more anhydrides of the compounds of formula 1. 18. The solid form of claim 17, wherein the one or more anhydrides is Compound 2: or a pharmaceutically acceptable salt, hydrate or solvate thereof. 19. A solid form comprising a crystalline compound of formula 2: or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein the crystalline compound of formula 2 is a Form I crystal form of formula 2 having an X-ray powder diffraction pattern comprising peaks at approximate peak positions of 6.32±0.10, 12.69±0.10, and 26.77±0.10 degrees 2θ, and at least one peak at an approximate peak position of 9.64±0.10, 11.20±0.10, 13.14±0.10, 14.67±0.10, 15.19±0.10, 16.85±0.10, 17.27±0.10, 17.44±0.10, 17.69±0.10, 17.96±0.10, 18.55±0.10, 19.04±0.10, 21.57±0.10, 22.47±0.10, 22.68±0.10, 23.37±0.10, 24.45±0.10, 24.66±0.10, 25.14±0.10, 25.49±0.10, and 27.71±0.10 degrees 2θ. 20. The solid form according to claim 19, wherein the solid form is substantially free of a compound of formula IMP-1, formula IMP-2, formula IMP-3, or formula IMP-4: 21. The solid form of claim 20, wherein the solid form is substantially free of an amorphous compound of formula 2. 22. The solid form of claim 19, wherein the solid form is substantially free of other crystalline forms of the compound of formula 2. 23. The solid form of claim 19, wherein the solid form is substantially free of a crystalline compound of formula 1: or other anhydrides of the compound of formula 2. 24. The solid form of claim 19 having an X-ray powder diffraction pattern further comprising a peak at approximately 17.69±0.10 degrees 2θ. 25. The solid form of claim 19 having an X-ray powder diffraction pattern further comprising peaks at approximate peak positions of 9.64±0.10, 11.20±0.10, 13.14±0.10, 14.67±0.10, 15.19±0.10, 16.85±0.10, 17.27±0.10, 17.44±0.10, 17.69±0.10, 17.96±0.10, 18.55±0.10, 19.04±0.10, 21.57±0.10, 22.47±0.10, 22.68±0.10, 23.37±0.10, 24.45±0.10, 24.66±0.10, 25.14±0.10, 25.49±0.10, and 27.71±0.10 degrees 2θ. 26. The solid form of claim 19 having an X-ray powder diffraction pattern further comprising peaks at approximate peak positions of 9.64±0.10, 11.20±0.10, 11.51±0.10, 13.14±0.10, 14.67±0.10, 15.19±0.10, 16.85±0.10, 17.27±0.10, 17.44±0.10, 17.69±0.10, 17.96±0.01, 18.55±0.10, 19.04±0.10, 19.42±0.10, 20.36±0.10, 20.84±0.10, 21.57±0.10, 22.47±0.10, 22.68±0.10, 22.99±0.10, 23.37±0.10, 24.45±0.10, 24.66±0.10, 25.14±0.10, 25.49±0.10, 27.71±0.10, 28.26±0.10, and 29.03±0.10 degrees 2θ. 27. A pharmaceutical composition comprising the solid form of claim 1 and a pharmaceutically acceptable excipient. 28. A pharmaceutical composition comprising the solid form of claim 2 and a pharmaceutically acceptable excipient. 29. A pharmaceutical composition comprising the solid form of claim 19 and a pharmaceutically acceptable excipient.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (95)
Barnes Keith D. ; Hu Yulin, 1, 4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents.
Bezborodov Vladimir S. (Minsk SUX) Grinkevich Oleg A. (Minsk SUX) Grebenkin Mikhail F. (Moscow SUX) Lapanik Valery I. (Minsk SUX) Minko Anatoly A. (Minsk SUX) Rzhussky Vitaly V. (Minsk SUX) Muravsky , 2-(4,3-Disubstituted phenyl)-5-alkyl-1,3,2-dioxaborinane derivatives and liquid crystal material.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Lou,Rongliang; Zhou,Jiacheng; Bhattacharjee,Ashoke; Chen,Shili; Chen,Yi; Farmer,Jay J.; Goldberg,Joel A.; Hanselmann,Roger; Orbin,Alia; Oyelere,Adegboyega K.; Salvino,Joseph M.; Springer,Dane M.; Tra, Biaryl heterocyclic compounds and methods of making and using the same.
Baker, Stephen J.; Akama, Tsutomu; Bellinger Kawahara, Carolyn; Hernandez, Vincent S.; Hold, Karin M.; Leyden, James J.; Maples, Kirk R.; Plattner, Jacob J.; Sanders, Virginia; Zhang, Yong Kang, Boron-containing small molecules.
Cavezzan Jacques (Villeurbanne FRX) Priou Christian (Villeurbanne FRX), Cationically crosslinkable polyorganosiloxanes and antiadhesive coatings produced therefrom.
Gray George W. (Cottingham GB3) Hird Michael (Hull GB3) Lacey David (Hull GB3) Toyne Kenneth J. (Hull GB3) Reiffenrath Volker (Rossdorf DEX) Wchtler Andreas (Griesheim DEX) Krause Joachim (Dieburg DE, Fluorinated oligophenyls and their use in liquid crystal materials.
Priou Christian (Villeurbanne FRX), Initators for the cationic crosslinking of polymers containing organofunctional groups, crosslinkable polyorganosiloxane.
Wand,Michael D.; More,Kundalika M.; Thurmes,William N., Liquid crystal compositions comprising an organogermanium compound and methods for using the same.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Benson Bradley J. (Chapel Hill NC) Chen Xiannong (Athens GA) Cianciolo George J. (Chapel Hill NC) Diaz Jose-Luis (Durham NC) Ishaq Khalid S. (Chapel Hill NC) Morris-Natschke Susan L. (Apex NC) Uhing , N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cyto.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Frances, Jean-Marc; Gambut, Lucille, Plastic material surface treatment with a polymerizable and/or crosslinkable organic composition having reactive functions.
Schlosser Hubert (Glashutten/Taunus DEX) Wingen Rainer (Hattersheim/Main DEX) Manero Javier (Frankfurt am Main DEX), Process for cross-coupling aromatic boronic acids with aromatic halogen compounds or perfluoroalkylsulfonates.
Butlin, Margaret Anne; Butlin, Roger John; Hogan, Philip John; Meudt, Andreas, Protected forms of N-(3-methoxy-5-methylpiperazin-2-yl)-2-(4-[1,3,4,-oxadiazol-2-yl]phenyl)-pyridine-3-sulphonamide.
Barker Andrew J. (Macclesfield GB2) Hughes Leslie R. (Macclesfield GB2) Marsham Peter R. (Poynton GB2) Oldfield John (Wilmslow GB2) Pegg Stephen J. (Macclesfield GB2), Quinazoline derivatives possessing anti-tumor activity.
Reiffenrath Volker (Rossdorf) Krause Joachim (Dieburg) Wchtler Andreas (Griesheim) Geelhaar Thomas (Mainz DEX) Coates David (Wimborne GBX) Sage Ian (Broadstone GBX) Greenfield Simon (Poole GBX), Smectic liquid-crystal medium.
Priou Christian ; Soldat Andre,FRX ; Kerr ; III Stuart R. ; Beaty Reeshemah, Stable polyorganosiloxane based compositions with cross-linkable functional groups and their use for producing antiadhesive coating.
Bach Nicholas James ; Draheim Susan Elizabeth ; Dillard Robert Delane ; Mihelich Edward David ; Sawyer Jason Scott ; Beight Douglas Wade ; Phillips Michael LeRoy ; Suarez Tulio ; Sall Daniel Jon ; Ba, Substituted tricyclics.
Fuss Robert Walter,DEX ; Manero Javier,DEX ; Schlosser Hubert,DEX ; Wingen Rainer,DEX, Thiadiazole derivatives, process for their preparation, and their use as precursors for the production of liquid crystal.
Hudson Derek (San Anselmo CA) Johnson Charles R. (Berkeley CA) Ross Michael J. (Hillsborough CA) Shoemaker Kevin R. (San Francisco CA) Cass Robert T. (San Mateo CA) Giebel Lutz B. (Burlingame CA), Thin film HPMP matrix systems and methods for constructing and displaying ligands.
Marie-Christine Cotting FR; Gerard Joubert FR; Olivier Loubet FR, Use of silicone compositions cross-linkable by cationic process under UV radiation and of an onium borate type photoinitiator for coating flat joints, particularly cylinder head gaskets.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.